Latest Breaking News On - யுங் தாடை மருந்து தொழில்துறை இணை - Page 1 : comparemela.com

AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Shares of Cadila Healthcare rose as much as 1.72 per cent to hit an intraday high of Rs 633.20 after it informed exchanges that Zydus Cadila has entered into an agreement with TLC, a Taiwan-based clinical-stage, specialty pharmaceutical company for marketing Mucormycosis or Black Fungus drug in the country. Zydus Cadila signed a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India, Cadila Healthcare said in a press release.

Zydus cadilaYung shin pharmaceutical industrial coBlack fungusCadila healthcareAmphotericinb liposomeYung shin pharmaceutical industrialஜய்துச் காடிலாயுங் தாடை மருந்து தொழில்துறை இணைகருப்பு பூஞ்சைகாடிலா சுகாதாரம்யுங் தாடை மருந்து தொழில்துறை